Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations

Hypertension

Volumn 54, Issue 1, 2009, Pages 63-70

  Caton, Alissa R ^a,b   Bell, Erin M ^a   Druschel, Charlotte M ^a,b   Werler, Martha M ^c   Lin, Angela E ^d   Browne, Marilyn L ^a,b   McNutt, Louise Anne ^a   Romitti, Paul A ^e   Mitchell, Allen A ^c   Olney, Richard S ^f   Correa, Adolfo ^f  

^a UNIVERSITY AT ALBANY   (United States)

^b NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^c BOSTON UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Antihypertensive agents; Cardiovascular malformations; Congenital malformations; Hypertension; Pregnancy

Indexed keywords

ACETAZOLAMIDE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; LABETALOL; LISINOPRIL; METHYLDOPA; METOPROLOL; NIFEDIPINE; NISOLDIPINE; PINDOLOL; PROPRANOLOL; QUINAPRIL; RAMIPRIL; TRIAMTERENE; UNINDEXED DRUG; VASODILATOR AGENT; VERAPAMIL;

ADULT; ANTIHYPERTENSIVE THERAPY; AORTA COARCTATION; AORTA STENOSIS; ARTICLE; BIRTH CERTIFICATE; CARDIOVASCULAR MALFORMATION; CONTROLLED STUDY; DRUG USE; EBSTEIN ANOMALY; FALLOT TETRALOGY; FEMALE; FIRST TRIMESTER PREGNANCY; GEOGRAPHIC DISTRIBUTION; GREAT VESSELS TRANSPOSITION; HEALTH SURVEY; HEART ATRIUM SEPTUM DEFECT; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART RIGHT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART VALVE STENOSIS; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPERTENSION; HYPOPLASTIC LEFT HEART SYNDROME; INFANT; LIVE BIRTH; LUNG VEIN DRAINAGE ANOMALY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PULMONARY VALVE ATRESIA; PULMONARY VALVE STENOSIS; RISK FACTOR;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR ABNORMALITIES; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; INFANT, NEWBORN; LOGISTIC MODELS; MALE; MATERNAL AGE; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY TRIMESTER, FIRST; RISK ASSESSMENT; RISK FACTORS;

EID: 67649866339     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.129098     Document Type: Article

References (44)

1. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1-S22.
2. Afifi Y, Churchill D. Pharmacological treatment of hypertension in pregnancy. Curr Pharm Des. 2003;9:1745-1753.
3. Magee LA. Treating hypertension in women of child-bearing age and during pregnancy. Drug Saf. 2001;24:457-474.
4. Mulrow CD, Chiquette E, Ferrer RL, Sibai BM, Stevens KR, Harris M, Montgomery KA, Stamm K. Management of chronic hypertension during pregnancy. Evid Rep Technol Assess (Summ). 2000;14:1-4.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
6. Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol. 2002;100:369-377.
7. Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol. 2005;73:123-130.
8. CDC. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy-United States, Canada, and Israel, 1987-1995. MMWR Morb Mortal Wkly Rep. 1997;46: 240-242.
9. Mastrobattista JM. Angiotensin converting enzyme inhibitors in pregnancy. Semin Perinatol. 1997;21:124-134.
10. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev. 2006;82:23-28.
11. Schaefer C. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol. 2003;67:591-594.
12. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ. 1990;301:587-589.
13. Briggs GG, Freeman RK, Yaffe SJ. Atenolol. Drugs in Pregnancy and Lactation Update. 2003;16:10-15.
14. Lydakis C, Lip GY, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999;12: 541-547.
15. Ananth CV, Peedicayil A, Savitz DA. Effect of hypertensive diseases in pregnancy on birthweight, gestational duration, and small-for-gestational-age births. Epidemiology. 1995;6:391-395.
16. Haelterman E, Breart G, Paris-Llado J, Dramaix M, Tchobroutsky C. Effect of uncomplicated chronic hypertension on the risk of small-forgestational age birth. Am J Epidemiol. 1997;145:689-695.
17. Ridings JE, Palmer AK, Davidson EJ, Baldwin JA. Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996;10:43-49.
18. Reprotox. An information system on environmental hazards to human reproduction and development. Reserpine. 2001. Available at: http://www.reprotox.org. Accessed April 20, 2005.
19. Schardein JL. Chemically Induced Birth Defects. 3rd ed. New York, NY: Marcel Dekker, Inc; 2000:517-557.
20. Scott WJ Jr, Resnick E, Hummler H, Clozel JP, Burgin H. Cardiovascular alterations in rat fetuses exposed to calcium channel blockers. Reprod Toxicol. 1997;11:207-214.
21. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354: 2443-2451.
22. Lennestal R, Otterblad Olausson P, Kallen B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol. In press.
23. Ferencz C, Rubin JD, Loffredo CA, Magee CA, eds. Epidemiology of Congenital Heart Disease: The Baltimore-Washington Infant Study 1981-89. Mount Kisco, NY: Futura Publishing Co; 1993.
24. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton, CO: PSG Publishing Co; 1977.
25. Kallen BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol. 2003;17:255-261.
26. Sorensen HT, Czeizel AE, Rockenbauer M, Steffensen FH, Olsen J. The risk of limb deficiencies and other congenital abnormalities in children exposed in utero to calcium channel blockers. Acta Obstet Gynecol Scand. 2001;80:397-401.
27. Rasmussen SA, Lammer EJ, Shaw GM, Finnell RH, McGehee RE Jr, Gallagher M, Romitti PA, Murray JC. Integration of DNA sample collection into a multi-site birth defects case-control study. Teratology. 2002;66:177-184.
28. Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol. 2003;67:193-201.
29. Yoon PW, Rasmussen SA, Lynberg MC, Moore CA, Anderka M, Carmichael SL, Costas P, Druschel C, Hobbs CA, Romiti PA, Langlois PH, Edmonds LD. The National Birth Defects Prevention Study. Public Health Rep. 2001;116(suppl 1):32-40.
30. Botto LD, Lin AE, Riehle-Colarusso T, Malik S, Correa A. Seeking causes: classifying and evaluating congenital heart defects in etiologic studies. Birth Defects Res A Clin Mol Teratol. 2007;79:714-727.
31. Tanner K, Sabrine N, Wren C. Cardiovascular malformations among preterm infants. Pediatrics. 2005;116:833-838.
32. Clark EB. Mechanisms in the pathogenesis of congenital cardiac malformations. In: Pierpont ME, Moller JH, eds. The Genetics of Cardiovascular Disease. Boston, MA: Martinus Nijhoff Publishing; 1986:3-11.
33. Clark EB. Pathogenetic mechanisms of congenital cardiovascular malformations revisited. Semin Perinatol. 1996;20:465-472.
34. Hajdu J, Beke A, Marton T, Hruby E, Pete B, Papp Z. Congenital heart diseases in twin pregnancies. Fetal Diagn Ther. 2006;21:198-203.
35. Karatza A, Wolfenden J, Taylor M, Wee L, Fisk N, Gardiner H. Influence of twin-twin transfusion syndrome on fetal cardiovascular structure and function: prospective case-control study of 136 monochorionic twin pregnancies. Heart. 2002;88:271-277.
36. Szwast A, Rychik JR. Current concepts in fetal cardiovascular disease. Clin Perinatol. 2005;32:857-875.
37. deAlmeida A, McQuinn T, Sedmera D. Increased ventricular preload is compensated by myocyte proliferation in normal and hypoplastic fetal chick left ventricle. Circ Res. 2007;100:1363-1370.
38. Kallen BA. Methodological issues in the epidemiological study of the teratogenicity of drugs. Congenit Anom (Kyoto). 2005;45:44-51.
39. Mitchell AA, Cottler LB, Shapiro S. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol. 1986;123: 670-676.
40. Mitchell AA. Special considerations in studies of drug-induced birth defects. In: Strom BL, ed. Pharmacoepidemiology. New York, NY: John Wiley & Sons, Ltd; 2000:749-763.
41. Rockenbauer M, Olsen J, Czeizel AE, Pedersen L, Sorensen HT. Recall bias in a case-control surveillance system on the use of medicine during pregnancy. Epidemiology. 2001;12:461-466.
42. Swan SH, Shaw GM, Schulman J. Reporting and selection bias in case-control studies of congenital malformations. Epidemiology. 1992;3: 356-363.
43. Werler MM, Pober BR, Nelson K, Holmes LB. Reporting accuracy among mothers of malformed and nonmalformed infants. Am J Epidemiol. 1989;129:415-421.
44. Ward RM. Difficulties in the study of adverse fetal and neonatal effects of drug therapy during pregnancy. Semin Perinatol. 2001;25:191-195.